


Business Strategy

Health Care

- 3 Chapter 1 Our Vision
- 22 Chapter 2 Sustainable Growth Strategy
- 23 Members of the One Global Leadership Team
- 24 Executable Plan Based on the “Forging the future” Management Policy
- 31 Message from the CFO
- Business Strategy
- 34 Message from the Business Unit Heads
- 35 Specialty Materials
- 39 Industrial Gases
- 40 Health Care**
- 41 MMA
- 42 Petrochemicals and Carbon Products
- 43 Message from the Chief Supply Chain Officer
- Innovation
- 44 Message from the CTO
- 45 Innovation Strategy
- 47 Intellectual Property Strategy
- Digital
- 48 Message from the CDO
- 49 Digital Strategy
- 52 Message from the Chief Strategy Officer
- 53 Building an In-House Understanding of the Management Policy
- 56 Chapter 3 Strengthening ESG Activities
- 95 Chapter 4 Financial/Non-Financial Information

Strengthening the pipeline and maximizing product value


To achieve our fiscal 2025 targets, we are focusing on (1) maximizing the value of priority products in Japan and the United States and (2) strengthening partnering and establishing new sales and development alliances. We restructured our business in fiscal 2022, including withdrawal from the business operated by Medicigo Inc. that was developing a vaccine against COVID-19. We will now focus R&D spending on indications in the core areas of central nervous system, immuno-inflammation, and oncology, with the goal of strengthening our pipeline and maximizing product value.



Strategic focus

- Advance precision medicine through upgraded R&D processes
- Focus innovation development on rare diseases and continue to invest in a new pipeline
- Leverage partnerships for development and sales

SWOT analysis



New treatment option for ALS patients

The oral suspension formulation of edaravone was approved as a treatment for amyotrophic lateral sclerosis (ALS) in the United States in May 2022, in Canada in November, in Japan in December, and in Switzerland in May 2023.

This oral suspension formulation of edaravone contains the same active ingredient as the intravenous infusion formulation *RADICUT* (U.S. product name: *RADICAVA*). We undertook its development with the aim of reducing burdens on ALS patients such as injection pain and outpatient visits. Previously, intravenous infusion was the only available route of administration, but now there is a new treatment option.



Area	Focus	Targeted indications	Key markets	MCG Group's key growth products	Launch plans for main pipeline programs			
					FY2022	FY2023	FY2024	From FY2025
Central nervous system	Development, sales	ALS Tardive dyskinesia	U.S., Japan	RADICAVA DYSVAL	MT-1186 ALS (oral suspension) (U.S., Canada)	MT-1186 ALS (oral suspension) (Japan)*2	ND0612 Parkinson's disease (global)	MT-0551 Myasthenia gravis (Japan)
					MT-5199 Tardive dyskinesia (Japan)			
Immuno-inflammation	Development, sales	Inflammatory bowel disease Erythropoietic protoporphyria	U.S., Japan	STELARA MT-7117				MT-0551 IgG4-related disease (Japan) MT-7117 Erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP) (global)
Diabetes and kidney	Sales	Type 2 diabetes Chronic kidney disease (CKD) associated with type 2 diabetes	Japan	MOUNJARO CANAGLU	TA-7284 CKD associated with type 2 diabetes*1 (Japan) MP-513 Type 2 diabetes (China)		TA-7284 OD tablets Type 2 diabetes, CKD associated with type 2 diabetes*1 (Japan)	
Oncology	Development	Rare cancers	U.S., Japan	MT-2111				MT-2111 Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) (Japan)

*1 CKD associated with type 2 diabetes, but excludes patients with end-stage renal failure or undergoing dialysis

*2 Approved in Switzerland

(As of August 2023)